NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Antikor Biopharma

Antikor Biopharma

Private
StevenageHealthcare & Life Scienceshttps://www.antikor.co.uk/

Last Round

Grant

Nov 1, 2024

Total Funding Raised

$1.51M

Company Overview

Antikor Biopharma is a biotechnology company that specializes in the discovery and development of small-format Antibody Fragment Drug Conjugates (FDCs) for the treatment of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

antibody-fragment drug conjugatesFDConcology therapeuticsantibody-drug conjugatesADCbioconjugationsolid tumor treatmenttargeted cancer therapybiotech licensingpreclinical drug developmentcytotoxic payloadsantibody fragmentsnext-gen ADCsdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Antikor Biopharma Comparables

Compare Antikor Biopharma with similar companies based on industry and business-model similarity.

Antikor Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Crescendo Biologics Ltd.
75%
Avacta Group
70%
Bicycle Therapeutics
69%

Antikor Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 1, 2024
GrantApr 1, 2022
VC RoundJul 31, 2019

Key People

Founding team and executive leadership

Mahendra Deonarain

Chief Executive Officer, Chief Science and Operating Officer

Executive Team

Antikor Biopharma Investors

Notable investors and investment history

Antikor Biopharma investors
InvestorRounds
Essex Bio-TechnologyVC Round
Innovate UKGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 1, 2024

    $630K raised from Innovate UK.

  • Apr 1, 2022

    Secured $1.51M in grant funding from Innovate UK.

Antikor Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Antikor Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Antikor Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersStevenage
Employee Range12
Year Founded2014
Last FundingNov 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.